Skip to content
i2E
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Search

Biotech firm poised to expand in OKC

Get in Touch

By Brianna Bailey

Copyright © 2013, The Oklahoma Publishing Company

With the help of a National Institutes of Health grant to develop new drug-discovery instruments and private equity investment, Oklahoma City-based biotech company SensiQ Technologies is poised for expansion.

The company’s lab, housed in the Presbyterian Health Foundation Research Park, makes devices to study biomolecular interaction that helps to develop new drugs.

The company recently was awarded Phase 1 funding from the NIH to further its development of technologies that measure drug interactions. The company will receive about $1.3 million through the NIH FastTrack program to help fund the research.

“This will help us develop the next generation of these devices that can be used to measure drug interactions more efficiently,” said David Goad, research scientist for SensiQ.

SensiQ’s top-of the-line machine is a roughly 70-pound gadget a bit larger than a toaster oven called the SensiQ Pioneer. The Pioneer retails for about $200,000. The company also makes other models that measure the same biomolecular reactions for less than $10,000.

The machines use a patented injection method called OneStep to help measure chemical reactions.

“So our market is life science — a lot of our customers are the research universities and big pharma,” said Tom Jobe, chief operating officer for SensiQ.

The growing demand for new technology to aid the discovery of new pharmaceuticals also is helping the company grow, Jobe said.

The Oklahoma City-based private equity firm TechVen Partners acquired SensiQ in 2012. Led by inventor and businessman Colin Cummings, TechVen provides venture capital for early-stage technology companies.

The company also qualified earlier this year for job-creation incentives through Oklahoma’s Quality Jobs program.

SensiQ has qualified for up to $2.19 million in tax money to develop up to 103 new jobs over the next 10 years through the job creation program. The program provides growing companies in the state quarterly cash payments based on payroll numbers.

Click here to read the article at newsok.com.

 

 

  • admin
    admin

More News

Loading...
Black doctor smiling with stethoscope
Blog, i2E
02.09.23

Titan Intake Automates Patient Referrals to Accelerate Care

Read more
man and woman reviewing paperwork at a table
Blog, i2E, News
01.10.23

Stories of Oklahoma Innovation: Building a Startup

Read more
woman in lab conducting a study
Blog, i2E
12.13.22

Bayesic Technologies Improves Effectiveness and Efficiency of Data Analysis in Healthcare

Read more
Bison grazing fields
Blog
11.30.22

Bison Underground Merges Nature, Science, and Technology to Tackle Climate Change

Read more
African American family sitting on couch reading and chatting
Blog, E3, i2E
11.22.22

Fokes Connects Families, Caregivers and Care Agencies for Smoother Communications and Care 

Read more
i2e blog post graphic
Blog, News
11.03.22

Introducing: Stories of Oklahoma Innovation

Read more
Default Featured Image
OKBio
06.28.22

Oklahoma Grown! i2E Invests in BIO startups

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma Medical Research Foundation BIO

Read more
Default Featured Image
OKBio
06.13.22

Moleculera Labs BIO

Read more
Default Featured Image
OKBio
06.13.22

University of Oklahoma Health Sciences Center BIO

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma State University BIO

Read more
Default Featured Image
OKBio
06.13.22

ECHO Investment Capital BIO

Read more
i2E

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
+1 (405) 235.2305

Tulsa Office

100 S. Cincinnati Ave – Suite 514
Tulsa, OK 74103
+1 (918) 582.5592

  • Client Portfolio
  • About Us
  • Media
  • Events
  • Contact
  • Resources

© 2022 i2E Privacy Policy

Follow us:

Facebook Twitter Linkedin

Programs

  • E3
  • ACT Tulsa
  • Love's Entrepreneur's Cup
  • OKBio
  • Client Portfolio

Services

  • Access to Funding
  • Venture Advisory Services
  • Contact
  • About
  • Our Values
  • Our Team
  • Board of Directors
  • Corporate Partners
  • Media
i2E